Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Peter Schmid; Javier Cortés; Rebecca Dent; Lajos Pusztai; Heather McArthur; Sherko Kümmel; Jonas Bergh; Carsten Denkert; Yeon Hee Park; Rina Hui; Nadia Harbeck; Masato Takahashi; Michael Untch; Peter A. Fasching; Fátima Cardoso; Jay Andersen; Debra Patt; Michael Danso; Marta Ferreira; Marie-Ange Mouret-Reynier; Seock-Ah Im; Jin-Hee Ahn; María Gion; Sally Baron-Hay; Jean-François Boileau; Yu Ding; Konstantinos Tryfonidis; Gursel Aktan; Vassiliki Karantza; Joyce O'Shaughnessy

doi:10.1056/nejmoa2112651

Abstract

In patients with early triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab after surgery, resulted in significantly longer event-free survival than neoadjuvant chemotherapy alone. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).

Affiliated Institutions

National University Cancer Institute, Singapore SG

Related Publications

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid , Javier Cortés , Lajos Pusztai +18 more

Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plu...

2020 New England Journal of Medicine 2718 citations

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo +97 more

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...

2020 The Lancet 1658 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer , B. Yа. Alekseev , Sun Young Rha +35 more

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme;...

2021 New England Journal of Medicine 1597 citations

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini , Elizabeth R. Plimack , V.P. Stus +24 more

Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progress...

2019 New England Journal of Medicine 3200 citations

Publication Info

Year: 2022
Type: article
Volume: 386
Issue: 6
Pages: 556-567
Citations: 980
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

980

OpenAlex

Cite This

APA Style

                            
                                
                                    Peter Schmid, 
                                
                                    Javier Cortés, 
                                
                                    Rebecca Dent
                                
                                et al.
                            
                            (2022). 
                            Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. 
                            New England Journal of Medicine
                            , 386
                            (6)
                            , 556-567.
                            https://doi.org/10.1056/nejmoa2112651
                        

Identifiers

DOI: 10.1056/nejmoa2112651